NO315967B1 - Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse - Google Patents

Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse Download PDF

Info

Publication number: NO315967B1
Authority: NO; Norway
Prior art keywords: mania; treatment; gabapentin; compounds; compound
Prior art date: 1995-05-15

Application number

NO19975234A

Other languages

English (en)

Norwegian (no)

Other versions

NO975234D0 (no

NO975234L (no

Inventor

Atul Chandra Pande

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-15

Filing date

1997-11-14

Publication date

2003-11-24

1997-11-14 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1997-11-14 Publication of NO975234D0 publication Critical patent/NO975234D0/no

1997-11-14 Publication of NO975234L publication Critical patent/NO975234L/no

2003-11-24 Publication of NO315967B1 publication Critical patent/NO315967B1/no

Links

UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims abstract description 27
206010026749 Mania Diseases 0.000 title claims abstract description 19
229960002870 gabapentin Drugs 0.000 title claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 24
208000020925 Bipolar disease Diseases 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
230000001154 acute effect Effects 0.000 claims abstract description 4
230000001684 chronic effect Effects 0.000 claims abstract description 3
230000000306 recurrent effect Effects 0.000 claims abstract 2
125000000217 alkyl group Chemical group 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
208000024891 symptom Diseases 0.000 claims description 3
230000002265 prevention Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 4
239000000203 mixture Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
206010013486 Distractibility Diseases 0.000 description 3
206010022998 Irritability Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
MKGSCDBHUPQQMX-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCC1 MKGSCDBHUPQQMX-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
208000019116 sleep disease Diseases 0.000 description 2
208000022925 sleep disturbance Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
MXNASYICBPHSLF-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCCCC1 MXNASYICBPHSLF-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010013496 Disturbance in attention Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018671 Grandiosity Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
208000027626 Neurocognitive disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000012761 aggressive behavior Diseases 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
HJQOMCVHLXVRAK-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound CCCCOC(=O)CC1(CN)CCCCCC1 HJQOMCVHLXVRAK-UHFFFAOYSA-N 0.000 description 1
IPNWNGVBVWEYLT-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCCCOC(=O)CC1(CN)CCCCC1 IPNWNGVBVWEYLT-UHFFFAOYSA-N 0.000 description 1
WLKXAEISUKOGGG-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cyclopentyl]acetate Chemical compound CCCCOC(=O)CC1(CN)CCCC1 WLKXAEISUKOGGG-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
-1 cyclic amino acids Chemical class 0.000 description 1
PQCNPWAMVMHDID-UHFFFAOYSA-N ethyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCOC(=O)CC1(CN)CCCCC1 PQCNPWAMVMHDID-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000001761 ethyl methyl cellulose Substances 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
BPUUTTKHBSNDRT-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound COC(=O)CC1(CN)CCCCCC1 BPUUTTKHBSNDRT-UHFFFAOYSA-N 0.000 description 1
SYKKFHNKTXXXCK-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound COC(=O)CC1(CN)CCCCC1 SYKKFHNKTXXXCK-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Beans For Foods Or Fodder (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pyridine Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

NO19975234A 1995-05-15 1997-11-14 Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse NO315967B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/440,570 US5510381A (en)	1995-05-15	1995-05-15	Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en)	1995-05-15	1996-04-26	A method of treatment of mania and bipolar disorder

Publications (3)

Publication Number	Publication Date
NO975234D0 NO975234D0 (no)	1997-11-14
NO975234L NO975234L (no)	1997-11-14
NO315967B1 true NO315967B1 (no)	2003-11-24

Family

ID=23749281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975234A NO315967B1 (no)	1995-05-15	1997-11-14	Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse

Country Status (19)

Country	Link
US (1)	US5510381A (de)
EP (1)	EP0825857B1 (de)
JP (1)	JPH11505244A (de)
AT (1)	ATE218857T1 (de)
AU (1)	AU702435B2 (de)
CA (1)	CA2215923C (de)
CZ (1)	CZ288072B6 (de)
DE (1)	DE69621799T2 (de)
DK (1)	DK0825857T3 (de)
EE (1)	EE03420B1 (de)
ES (1)	ES2177783T3 (de)
GE (1)	GEP20002014B (de)
HU (1)	HUP9802087A3 (de)
NO (1)	NO315967B1 (de)
NZ (1)	NZ307366A (de)
PT (1)	PT825857E (de)
SK (1)	SK281982B6 (de)
WO (1)	WO1996036328A1 (de)
ZA (1)	ZA963826B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6372792B1 (en)	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
US6001876A (en)	1996-07-24	1999-12-14	Warner-Lambert Company	Isobutylgaba and its derivatives for the treatment of pain
AU9318398A (en)	1997-10-07	1999-04-27	Warner-Lambert Company	Process for preparing a cyclic amino acid anticonvulsant compound
CU23048A3 (es)	1997-10-27	2005-06-24	Warner Lambert Co	Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
US7309719B1 (en)	1998-05-15	2007-12-18	Warner Lambert Company, Llc	Stabilized pharmaceutical preparation of gamma-aminobutyric acid derivatives and process for preparing the same
PL205145B1 (pl) *	1998-05-15	2010-03-31	Warner Lambert Co	Trwała kompozycja stała zawierająca pochodną 4-amino-3-podstawionego kwasu butanowego oraz sposób jej wytwarzania
BR9910697A (pt)	1998-05-26	2001-01-30	Warner Lambert Co	Compostos aminoácidos comprimidos estruturalmente tendo afinidade à subunidade alfa2delta de um canal de cálcio
PL345338A1 (en) *	1998-07-09	2001-12-17	Warner Lambert Co	Method for the treatment of insomnia
NZ510920A (en) *	1998-10-16	2002-08-28	Warner Lambert Co	Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
US6436974B1 (en)	1999-06-02	2002-08-20	Warner-Lambert Company	Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) *	1999-10-07	2002-06-30	Warner Lambert Co	Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AU2001266992B8 (en) *	2000-06-16	2005-12-01	Teva Pharmaceutical Industries Ltd.	Stable gabapentin having pH within a controlled range
SK17922002A3 (sk) *	2000-06-26	2003-11-04	Warner-Lambert Company	Obdoby gabapentínu na liečenie porúch spánku
US20030119908A1 (en) *	2001-12-21	2003-06-26	Zambon Group S.P.A.	Stable gabapentin compositions
ITMI20012750A1 (it)	2001-12-21	2003-06-21	Procos Spa	Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
WO2011151708A1 (en)	2010-06-01	2011-12-08	Rubicon Research Private Limited	Gastroretentive dosage forms of gaba analogs
WO2015144825A1 (en)	2014-03-27	2015-10-01	Sanovel Ilac Sanayi Ve Ticaret A.S.	Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) *	2022-04-13	2023-06-06	Green Sky Creations LLC	Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2460891C2 (de) *	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) *	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
US4355044A (en) *	1980-12-19	1982-10-19	Bernardo Heller	D-Phenylalanine treatment
US5084479A (en) *	1990-01-02	1992-01-28	Warner-Lambert Company	Novel methods for treating neurodegenerative diseases
US5086072A (en) *	1990-06-18	1992-02-04	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) *	1990-10-12	1991-06-18	Warner-Lambert Company	Method of treating depression

1995
- 1995-05-15 US US08/440,570 patent/US5510381A/en not_active Expired - Fee Related
1996
- 1996-04-26 EP EP96913852A patent/EP0825857B1/de not_active Expired - Lifetime
- 1996-04-26 SK SK1528-97A patent/SK281982B6/sk unknown
- 1996-04-26 NZ NZ307366A patent/NZ307366A/en unknown
- 1996-04-26 HU HU9802087A patent/HUP9802087A3/hu unknown
- 1996-04-26 ES ES96913852T patent/ES2177783T3/es not_active Expired - Lifetime
- 1996-04-26 DE DE69621799T patent/DE69621799T2/de not_active Expired - Fee Related
- 1996-04-26 CZ CZ19973558A patent/CZ288072B6/cs not_active IP Right Cessation
- 1996-04-26 CA CA002215923A patent/CA2215923C/en not_active Expired - Fee Related
- 1996-04-26 PT PT96913852T patent/PT825857E/pt unknown
- 1996-04-26 WO PCT/US1996/005898 patent/WO1996036328A1/en active IP Right Grant
- 1996-04-26 DK DK96913852T patent/DK0825857T3/da active
- 1996-04-26 GE GEAP19964027A patent/GEP20002014B/en unknown
- 1996-04-26 JP JP8534854A patent/JPH11505244A/ja not_active Ceased
- 1996-04-26 EE EE9700302A patent/EE03420B1/xx not_active IP Right Cessation
- 1996-04-26 AU AU56689/96A patent/AU702435B2/en not_active Ceased
- 1996-04-26 AT AT96913852T patent/ATE218857T1/de not_active IP Right Cessation
- 1996-05-14 ZA ZA963826A patent/ZA963826B/xx unknown
1997
- 1997-11-14 NO NO19975234A patent/NO315967B1/no unknown

Also Published As

Publication number	Publication date
ES2177783T3 (es)	2002-12-16
ATE218857T1 (de)	2002-06-15
NO975234D0 (no)	1997-11-14
HUP9802087A3 (en)	1999-08-30
DK0825857T3 (da)	2002-09-30
US5510381A (en)	1996-04-23
EE9700302A (et)	1998-06-15
NZ307366A (en)	1999-10-28
MX9707269A (es)	1997-11-29
CZ355897A3 (cs)	1998-02-18
PT825857E (pt)	2002-11-29
DE69621799T2 (de)	2003-01-02
AU5668996A (en)	1996-11-29
EP0825857A1 (de)	1998-03-04
EP0825857B1 (de)	2002-06-12
SK152897A3 (en)	1999-05-07
NO975234L (no)	1997-11-14
CZ288072B6 (cs)	2001-04-11
WO1996036328A1 (en)	1996-11-21
SK281982B6 (sk)	2001-09-11
CA2215923C (en)	2001-10-09
JPH11505244A (ja)	1999-05-18
EE03420B1 (et)	2001-06-15
ZA963826B (en)	1996-11-21
CA2215923A1 (en)	1996-11-21
DE69621799D1 (de)	2002-07-18
HUP9802087A2 (hu)	1998-12-28
AU702435B2 (en)	1999-02-18
GEP20002014B (en)	2000-04-10

Publication	Publication Date	Title
NO315967B1 (no)	2003-11-24	Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse
EP1121114B1 (de)	2007-01-10	Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
EP1885379B1 (de)	2016-07-20	Verbindungen und methoden zur behandlung von anfällen und paroxysmalen erkrankungen
EP0552240B1 (de)	1998-03-18	Neues verfahren zur behandlung von depression
HUE033180T2 (en)	2017-11-28	Peptide compounds for the treatment of difficult to cure epileptic diseases
US4636494A (en)	1987-01-13	Process and composition for treating disorders by administering amphetamine and choline
RU2184562C2 (ru)	2002-07-10	Применение ладана для лечения болезни альцгеймера
US20170165282A1 (en)	2017-06-15	Use of beta-nicotinamide mononucleotide in preparation of drugs for preventing and treating arteriosclerosis and cardio-cerebrovascular diseases, and drugs containing the same
KR20170137910A (ko)	2017-12-13	제약 분야에서의 r―옥시라세탐 응용
US4346084A (en)	1982-08-24	Process and composition for treating disorders by administering lithium and choline
EP0615750A2 (de)	1994-09-21	Behandlung einer Gruppe verwandter Erkrankungen
HUT50439A (en)	1990-02-28	Process for production of medical compositions suitable for treatment of sleep-disturbances and depression
CA3078609A1 (en)	2019-04-11	The use of a benzoate containing composition to treat glycine encephalopathy
MXPA97007269A (en)	1998-07-03	A method of treatment of mania and disorderbipo
BG63379B1 (bg)	2001-12-29	Метод за лечение на маниакално и двуполюсно заболяване
JP7257091B2 (ja)	2023-04-13	認知症の治療及び予防薬
JP6216913B1 (ja)	2017-10-18	医薬組成物
WO2022008966A1 (en)	2022-01-13	N - [4 - (trifluoromethoxy) benzylidene) nicotinohydrazide composition for oral administration
JPH0826979A (ja)	1996-01-30	免疫機能賦活剤
WO2018029685A1 (en)	2018-02-15	Compositions and methods for treating a fear memory